B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CBR1

MOLECULAR TARGET

carbonyl reductase 1

UniProt: P16152NCBI Gene: 8737 compounds

CBR1 (carbonyl reductase 1) is targeted by 7 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CBR1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1triclosan4.6098
2biochanin4.1462
3radicicol4.0657
4wedelolactone3.0019
5chrysin1.102
6monorden1.102
7Kaempferols0.691

About CBR1 as a Drug Target

CBR1 (carbonyl reductase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 7 compounds with documented CBR1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CBR1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.